Jul 03, 2021 07:59 AM IST
Among other deals, Sunidhi Securities & Finance acquired 10 lakh equity shares of Pricol at Rs 94.05 per share, while Alpha Leon Enterprises LLP purchased 4,22,237 equity shares of Vivimed Labs at Rs 22.65 per share.
- May 10, 2021 12:57 PM IST
Vivimed Labs in receipt of Government of India (DGHS) approval to manufacture and market Favipiravir tablets in the strengths of 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India, the company said in a regulatory filing.
- May 10, 2021 11:30 AM IST
Vivimed Labs received Government of India approval to manufacture and market Favipiravir Tablet 200 mg & 400 mg under brand name “Favulous” across India. It is used for the treatment of mild to moderate cases of Covid-19, the company said.
- Apr 16, 2021 01:33 PM IST
The share touched a 52-week high of Rs 23.62 and a 52-week low of Rs 9.70 on 25 August, 2020 and 27 May, 2020, respectively.
- Feb 16, 2021 01:11 PM IST
- Oct 13, 2020 09:52 AM IST
The share gained 41 percent in the last 9 months.
- Aug 12, 2019 02:53 PM IST
- Aug 12, 2019 02:53 PM IST
- May 31, 2019 04:53 PM IST
- May 31, 2019 04:50 PM IST
- Feb 15, 2019 03:51 PM IST
- Feb 15, 2019 03:50 PM IST
- Nov 16, 2018 09:47 AM IST
Selling in some small & mid-cap stocks started in the beginning of 2018 also —thanks to high valuations, but the pressure increased further post August
- Nov 15, 2018 04:29 PM IST
- Nov 15, 2018 04:26 PM IST
- Oct 05, 2018 11:25 AM IST
"The company's API manufacturing facility located in CUERNAVACA, Mexico was recently inspected by the United States Food and Drug Administration (USFDA) in compliance with their requirements," Vivimed Labs said in a BSE filing.
- Jan 01, 2018 01:55 PM IST
The company had earlier received USD 42.5 million from OrbiMed Asia in September 2017, Vivimed Labs said in a BSE filing.
- Sep 29, 2017 12:16 PM IST
Healthcare firm Orbimed Asia will invest USD 42.5 million in Vivimed Labs's subsidiary UQUIFA. In an interview to CNBC-TV18, Santosh Varalwar, CMD of Vivimed Labs spoke at length about the same.
- Sep 26, 2017 11:20 AM IST
Vivimed Labs Mascarene Ltd is the holding entity of the company's API (active pharmaceutical ingredient) business -- UQUIFA. In 2011, Hyderabad-based Vivimed Labs had acquired UQUIFA for USD 55 million.
- Jun 07, 2017 11:06 AM IST
After successful inspection, the US Food and Drug Administration has issued zero 483 observations for Spain facility.
- May 18, 2017 05:55 PM IST
The JV allows Strides to get access to Vivimed’s US FDA compliant formulation plant in Alathur, Tamil Nadu in addition to a portfolio of approved abbreviated new drug applications (ANDAs) and under development product pipeline for US market.
- Apr 20, 2017 12:27 PM IST
CNBC-TV18 learns from sources that Vivimed Labs is exploring various options to grow its US generics market and selling stake in the Chennai formulation plant.
- Feb 21, 2017 09:33 AM IST
The company plans to invest a total of around USD 84 million for expansion. Of this, USD 68.5 million will be raised by debt, which includes a loan from World Bank arm International Finance Corporation.
- Feb 15, 2017 09:33 AM IST
In an interview to CNBC-TV18, Deven Choksey, MD of KRChoksey Investment Managers shared his readings and outlook on specific stocks that came out with good quarterly numbers.
- Feb 15, 2017 08:00 AM IST
Tata Motors | Sun Pharma | DLF | Cadila Health | Jindal Steel | SpiceJet | Adani Enterprises | MOIL | Cox & Kings | HDIL | Liberty Shoes | Voltas | National Fertilisers | Ashiana Housing | Power Mech | Intellect Design Arena are stocks, which are in the news today.